Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJunnan LiDZDongfeng ZengYYYi‐Hsin Yang

Discussion

Loading...

Member takes

Overview

Retrospective study shows improvement in progression-free survival with ixazomib maintenance therapy in multiple myeloma, indicating a favorable safety profile.

Key Points

  • Progression-free survival improved significantly in both ASCT and non-ASCT cohorts with ixazomib maintenance therapy.
  • Adverse events were primarily hematologic and gastrointestinal but manageable, with 7.1% treatment discontinuation due to toxicity.
  • Cytogenetic risk stratification identified 55.1% of patients as high-risk according to mSMART criteria.
  • Real-world evidence highlights the effectiveness and tolerability of ixazomib for newly diagnosed multiple myeloma.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e244https://doi.org/10.1182/blood-2025-7544
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  2. 2Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025
  3. 3In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China2025
  4. 4Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma2025 · 2 citations
  5. 5An open-label rollover study to assess the long-term safety of ixazomib2025